跳至主要内容
临床试验/NCT03928938
NCT03928938已完成不适用

Follow-up of Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy by Electronic Patient Reported Outcomes-tool

Oulu University Hospital4 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2017年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
43
试验地点
4
主要终点
Change in the spectrum of patient reported symptoms

研究概览

简要总结

Electronic patient reported outcome (ePRO) tools have improved survival and quality of life (QoL) of cancer patients receiving chemotherapy, and in the follow-up of lung cancer patients. Current study investigates electronic patient reported outcome tool in the follow-up of cancer patients receiving immune checkpoint inhibitor therapy.

Current study aims to evaluate 1) patient reported symptoms and their severity, 2) Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events or survival, 3) Correlation between different symptoms and the correlation of symptoms to treatment side-effects, cancer progression, other medical events or survival,4) QoL of patients and correlation of changes in QoL to treatment side-effects, cancer progression, other medical events or survival, 5) Patient compliance, 6) Correlation of baseline laboratory values to treatment side-effects, cancer progression, other medical events or survival.

详细描述

Please see the Brief summary

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Advanced cancers
  • Immune checkpoint inhibitor therapy initiated within +/- 2wks
  • Patient compliant with the study procedures

排除标准

  • Immune checkpoint inhibitor therapy initiated > 2wks ago
  • General vulnerability affecting the participation in the trial
  • No internet access

结局指标

主要结局

Change in the spectrum of patient reported symptoms

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Percentages of patient reported symptoms using KaikuHealth 17 symptom e-questionnaire. Individual questions evaluate the presence of a specific symptom e.g. nausea. Questions are answered yes or no.

Change in Patient reported symptom severity

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Percentages of patient reported symptoms and their severity according NCI-CTCAE by KaikuHealth algorithm

Changes in patient compliance according to answering rate to symptom questionnaires

时间窗: At 4, 8, and 12weeks

Patient compliance using response rates (within one week) to symptom questionnaires in percentages from sent requests

Correlation of change in baseline Hb values compared to control Hb values to treatment side-effects, cancer progression, other medical events or survival.

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation of change in baseline Hb values compared to control Hb values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.

Correlation of change in baseline lymphocyte values compared to control lymphocyte values to treatment side-effects, cancer progression, other medical events or survival.

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation of change in baseline lymphocyte values compared to control lymphocyte values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.

Correlation of change in baseline neutrophil values compared to control neutrophil values to treatment side-effects, cancer progression, other medical events or survival.

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation of change in baseline neutrophil values compared to control neutrophil values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.

Change in the number of triggered alerts by the tool

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Number of triggered alerts by the tool and their correlation to treatment side-effects, cancer progression, other medical events in percentages or survival.

Correlation of change in baseline leucocyte values compared to control leucocyte values to treatment side-effects, cancer progression, other medical events or survival.

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation of change in baseline leucocyte compared to control leucocyte values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.

Correlation between changes in different symptoms and their severity to treatment side-effects, cancer progression, other medical events, or survival.

时间窗: At 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation between different patient reported symptoms and their severity to treatment side-effects, cancer progression or other medical events in percentages or survival.

Change in patient compliance according to answering rates to QLQ-C30 questionnaire

时间窗: At 4, 8, and 12weeks

Patient compliance using response rates to QLQ-C30 questionnaires (within one week) in percentages from sent requests. The QLQ-C30 questionnaire includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact. Subjects respond on a four-point-scale from "not at all" to "very much" for most items. Raw scores are linearly converted to a 0-100 scale. For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden. The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included).

Correlation of change in baseline CRP values compared to control CRP values to treatment side-effects, cancer progression, other medical events or survival.

时间窗: At Baseline, and at 2-3, 4-5, 6-7, 8-9, and 11-12weeks

Correlation of change in baseline CRP values compared to control CRP values at specific timepoints to treatment side-effects, cancer progression, other medical events or survival.

Changes in Quality of Life according to QLQ-C30 Summary scores

时间窗: At baseline, and at 4, 8, and 12weeks

The correlation of the Summary score of QLQ-C30 to treatment side-effects, cancer progression, or other medical events or survival. The Core Quality of life questionnaire (QLQ-C30) is a validated cancer health-related quality-of-life questionnaire that includes five function domains (physical, emotional, social, role, cognitive), eight symptoms (fatigue, pain, nausea/vomiting, constipation, diarrhea, insomnia, dyspnea, and appetite loss), as well as global health/quality of life and financial impact. Subjects respond on a four-point-scale from "not at all" to "very much" for most items. Raw scores are linearly converted to a 0-100 scale. For the functioning scales and global QoL higher scores indicate better functioning; for the symptom scales higher scores indicate higher symptom burden. The summary score of QLQ-C30 is calculated from the mean of 13 of 15 QLQ-C30 scales (the Global Quality of Life scale and the Financial Impact scale are not included).

Changes in Patient compliance Questionnaire

时间窗: At 4, 8, and 12weeks

Patient compliance using KaikuHealth e-questionnaire addressing usability (easiness to use from scale: very easy to very difficult; need of assistance to use the program: yes/no; how understandable are questions in symptom questionnaire from scale: totally agree to totally disagree) and user experience (use of the ePRO tool will better your cancer care: yes-no, do not know; use of the ePRO tool has been useful: yes-no-do not know; would you recommend the ePRO tool for cancer care: yes-no-do not know). Analysis is done on percentages of each answer choice at specific time point(s).

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jussi Koivunen

principal investigator, associate professor

Oulu University Hospital

研究点 (4)

Loading locations...

相似试验